NCT07052877Recruiting
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 23 Jun 2025
- Start date
- Dec 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Royal North Shore Hospital
- Diseases
- Glioblastoma
- NCT number
- NCT07052877
What you commit to
- Study type: Observational
- Planned participants: 20
- From Dec 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
- Does not fulfill PBS requirements for bevacizumab
Other illness
- No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
Other
- Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Who the study is looking for
- \> 18 year of age
- ECOG 0-2
- Able to provide informed consent for the study
- Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
- Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
- For bevacizumab treatment as per treating physician
- Able to comply with trial requirements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal North Shore Hospital Coordinator of this site? Confirm its status | Saint Leonards | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.